GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

116 calculators match

Most used

21
MELD-NaAssesses the severity of chronic liver diseaseChild-Pugh ScoreAssesses the prognosis of chronic liver disease, mainly cirrhosisFIB-4 IndexLiver fibrosis scoring indexAPRIAST to platelet ratio — liver fibrosisMaddrey's DFAlcoholic hepatitis severityGlasgow-BlatchfordUpper GI bleed risk stratificationGAHSGlasgow alcoholic hepatitis scoreMontreal IBDIBD classification — CD & UCMayo ScoreUlcerative colitis activityBISAP ScoreBedside index for severity of pancreatitisCLIF-SOFAOrgan failure scoring in cirrhosisAlcohol ContentStandard drinks & alcohol grams calculatorAARC-ACLFAcute-on-chronic liver failure gradePELD / CR ScorePediatric end-stage liver diseaseHarvey-BradshawCrohn's disease activity indexCTSICT severity index — pancreatitisRockall ScoreGI bleed rebleeding & mortality riskCAGEAlcohol use disorder screening (4 questions)MELD 3.0Updated MELD — sex-inclusive formulaAUDIT ScoreAlcohol use disorders identification testVOCAL-Penn ScorePost-operative mortality risk in cirrhosis surgery

Liver & Cirrhosis

17
ALBI GradeAlbumin-bilirubin liver function grade in HCCUKELD ScoreUK model for end-stage liver diseaseMELD-XIMELD excluding INR — for anticoagulated patientsWest Haven CriteriaHepatic encephalopathy gradingMilan CriteriaLiver transplant eligibility in hepatocellular carcinomaLI-RADS v2018 (CT/MRI)Liver observation category from size, APHE and major featuresBCLC StagingHepatocellular carcinoma stage and treatment allocationSimplified AIH CriteriaSimplified criteria for autoimmune hepatitisRevised Original AIH ScoreIAIHG 1999 comprehensive autoimmune hepatitis scoreSAAGSerum-ascites albumin gradient — cause of ascitesR FactorHepatocellular vs cholestatic pattern in liver injuryCLIF-C ACLFMortality prediction in acute-on-chronic liver failureKing's College CriteriaTransplant criteria in acute liver failureGALAD ScoreHCC detection from gender, age, AFP-L3, AFP and DCPMetroticket 2.0AFP-adjusted up-to-seven for HCC transplant eligibilityRUCAMCausality in drug- and herb-induced liver injuryBaveno VII CriteriacACLD, CSPH and sparing screening endoscopy

Fibrosis & MASLD

8
NAFLD Fibrosis ScoreAdvanced fibrosis probability in MASLD/NAFLDBARD ScoreBMI, AST/ALT ratio, diabetes — MASLD fibrosisFatty Liver IndexPredicts hepatic steatosis from routine labsFibrotic NASH Index (FNI)At-risk NASH probability from AST, HbA1c and HDLNAFLD Activity Score (NAS)Histologic activity grade — steatosis, inflammation, ballooningMEFIB IndexMRE + FIB-4 rule for significant fibrosis (≥F2) in MASLDFAST ScoreFibroScan-AST — at-risk NASH from LSM, CAP and ASTSAFE ScoreSteatosis-Associated Fibrosis Estimator for MASLD in primary care

Pancreas & Biliary

8
Ranson's CriteriaAcute pancreatitis severity at 48 hoursGlasgow-Imrie CriteriaAcute pancreatitis severity — the PANCREAS criteriaHAPSHarmless acute pancreatitis scoreTokyo Guidelines — CholangitisTG18 diagnosis and severity grade for acute cholangitisTokyo Guidelines — CholecystitisTG18 diagnosis and severity grade for acute cholecystitisBiliary Pain (Rome IV)Rome IV — defining biliary-type pain before interventionFunctional Pancreatic SODRome IV — pancreatic sphincter of Oddi disorderRevised Atlanta ClassificationAcute pancreatitis severity — mild, moderately severe, severe

IBD

9
Truelove & Witts CriteriaAcute severe ulcerative colitis — admission decisionUCEISUlcerative colitis endoscopic index of severitySCCAISimple clinical colitis activity index — symptoms onlyCDAICrohn's disease activity index — the trial standardSES-CDEndoscopic severity in Crohn's diseasePUCAIPaediatric ulcerative colitis activity indexTravis (Oxford) CriteriaDay 3 colectomy risk in acute severe ulcerative colitisHo IndexDay 3 steroid failure risk in acute severe ulcerative colitisRutgeerts ScorePostoperative Crohn's recurrence at ileocolonoscopy

GI Bleeding

7
EVendo ScorePredicts oesophageal varices needing treatmentForrest ClassificationPeptic ulcer bleeding — rebleeding risk at endoscopyAIMS65 ScoreUpper GI bleed mortality — five bedside criteriaOakland ScoreSafe-discharge risk for acute lower GI bleedingABC ScoreAge, blood tests, comorbidities — GI bleed mortalitySarin ClassificationEndoscopic classification of gastric varicesEGUS (Gastric Ulcer)Malignancy risk in a gastric ulcer, and who needs repeat endoscopy

Alcohol

2
ABIC ScoreAge, bilirubin, INR, creatinine — alcoholic hepatitisLille ModelSteroid response at day 7 in alcoholic hepatitis

Upper GI

4
Chicago Classification v4.0Oesophageal motility pattern from high-resolution manometryLA Classification (Oesophagitis)Los Angeles grade A–D for erosive oesophagitisPrague C & M CriteriaCircumferential and maximal extent of Barrett's oesophagusEREFS (Eosinophilic Oesophagitis)Endoscopic reference score — oedema, rings, exudates, furrows, stricture

Colorectal

3
Boston Bowel Prep ScaleColonoscopy preparation adequacy by segmentStool Osmotic GapOsmotic vs secretory diarrhoea from stool electrolytesATLAS Score (C. difficile)Predicted response to therapy in Clostridioides difficile infection

Functional GI

37
Bristol Stool ScaleStool form types 1–7 and colonic transitRome IV Criteria for IBSIrritable bowel syndrome diagnosis and subtypeFunctional ConstipationRome IV — two of six items, IBS excludedOpioid-Induced ConstipationRome IV — constipation tied to opioid therapyFunctional DiarrhoeaRome IV — loose stools without predominant painFunctional Bloating / DistensionRome IV — bloating without other bowel disorder criteriaUnspecified Functional Bowel DisorderRome IV — bowel symptoms fitting no other categoryCentrally Mediated Abdominal Pain (CAPS)Rome IV — continuous pain unrelated to gut eventsNarcotic Bowel SyndromeRome IV — opioid-induced hyperalgesia of the gutFaecal Incontinence (Rome IV)Rome IV — the criteria, and why nobody is askedFunctional Anorectal PainLevator ani, unspecified pain and proctalgia fugaxFunctional Defecation DisordersRome IV — dyssynergia and inadequate propulsionInfant RegurgitationRome IV — the happy spitter, and the alarm features that rule it outInfant ColicRome IV — recurrent unexplained crying in a well infant under 5 monthsInfant DyscheziaRome IV — straining before a soft stool, and why not to intervenePaediatric Functional ConstipationRome IV — two of six over one month, with overflow soiling as a criterionToddler's DiarrhoeaRome IV functional diarrhoea of childhood — painless, thriving childPaediatric Cyclic Vomiting SyndromeRome IV — both age bands, with different criteria for eachPaediatric Rumination SyndromeRome IV — infant and child/adolescent criteriaFunctional Nausea & Vomiting (Children)Rome IV — two separate disorders that can be met togetherAerophagiaRome IV — distension that increases through the dayPaediatric Functional DyspepsiaRome IV — four times a month, with PDS and EPS subtypingPaediatric Irritable Bowel SyndromeRome IV — plus the constipation clause clinicians missAbdominal MigraineRome IV — stereotypical incapacitating episodes weeks apartFunctional Abdominal Pain — NOSRome IV — the residual category, reached after the other threeNonretentive Faecal IncontinenceRome IV — soiling without retention, where laxatives make it worseFunctional DyspepsiaRome IV — with PDS and EPS subtypingRumination SyndromeRome IV — effortless regurgitation without retchingCyclic Vomiting SyndromeRome IV — stereotypical episodic vomitingCannabinoid HyperemesisRome IV — CVS pattern relieved by cannabis cessationChronic Nausea & VomitingRome IV — chronic nausea and vomiting syndromeBelching DisordersRome IV — supragastric vs gastric belchingFunctional HeartburnRome IV — heartburn with normal acid exposureReflux HypersensitivityRome IV — normal acid exposure, positive symptom associationFunctional Chest PainRome IV — non-cardiac, non-reflux chest painGlobusRome IV — painless lump-in-throat sensationFunctional DysphagiaRome IV — dysphagia with normal endoscopy and manometry
  1. Calculators
  2. /
  3. Narcotic Bowel Syndrome
Functional GI

Narcotic Bowel Syndrome

Rome IV — opioid-induced hyperalgesia of the gut

A structural diagnosis such as inflammatory bowel disease or chronic pancreatitis may be present — the criterion is that its character or activity does not account for the pain.

The paradox at the centre of this diagnosis: the opioid prescribed for the pain is causing it. Two or more of three characteristic patterns are required, and the pain must occur most days.

When to use
Use it in any patient on chronic or escalating opioids whose abdominal pain is getting worse rather than better. That combination — rising doses, rising pain — is the signal, and it is systematically misread as under-treatment because the intuitive interpretation of worsening pain on analgesia is that there is not enough analgesia. The criteria exist to interrupt that loop. A structural diagnosis may be present; what matters is whether its activity accounts for the pain. It does not apply to acute pain, to a stable dose with stable pain, or where the opioid is genuinely controlling symptoms.
Why use it
Because without the diagnosis the trajectory only goes one way. Pain worsens, the dose rises, the pain worsens further, and each escalation is justified by the deterioration it caused. Patients accumulate admissions, investigations and morphine-equivalent doses that would be remarkable in oncology, and the abdominal pain is worse at every step than it was at the start. Naming narcotic bowel syndrome converts that into a treatable situation with a clear plan — planned withdrawal with a neuromodulator in place — and gives both clinician and patient a reason to do the counterintuitive thing. It also protects patients from the alternative explanations that get reached for instead: repeat laparotomy, further imaging, and escalating immunosuppression in those who happen to carry an inflammatory bowel diagnosis.
Formula, evidence and interpretation

About the Rome IV Criteria for Narcotic Bowel Syndrome / Opioid-Induced GI Hyperalgesia

The opioid prescribed for the pain is causing it — that paradox is the entire disorder. Rome IV requires chronic or frequently recurring abdominal pain, occurring most days, treated with acute high-dose or chronic opioids; pain whose nature and intensity is not explained by a current or previous gastrointestinal diagnosis; and two or more of three patterns: pain that worsens or incompletely resolves with continued or escalating doses, marked worsening as the dose wanes with improvement when opioids are reinstated ('soar and crash'), or progressive escalation in the frequency, duration and intensity of episodes. The treatment is opioid withdrawal, which is the opposite of what the presentation demands.

On this page

  • Formula
  • Interpreting the result
  • Inputs
  • What it returns
  • How it is calculated
  • Facts & figures
  • Evidence
  • How it compares
  • Pearls & pitfalls
  • Critical actions
  • Why it exists
  • About the creator
  • Limitations
  • If you are the patient
  • FAQ
  • Related calculators
  • References

Formula

NBS = chronic/recurring abdominal pain most days on high-dose or chronic opioids AND pain unexplained by a GI diagnosis AND (≥ 2 of 3 characteristic patterns)
≥ 2 of 3
Worsening with escalation; soar and crash; progression of episode frequency, duration and intensity. Two are required, not one.
Not explained by a GI diagnosis
A structural diagnosis may coexist. The test is whether its character or activity accounts for the pain, not whether it exists.
  • There is no 3-month or 6-month timing rule in these criteria — the requirement is that pain occurs most days.
  • Rome IV explicitly permits a coexisting structural diagnosis, which is what makes the disorder diagnosable in patients with inflammatory bowel disease or chronic pancreatitis.
  • Opioid dose is described qualitatively as 'acute high-dose or chronic', with no threshold specified.
  • The 'soar and crash' pattern is the one most often misinterpreted, because improvement on reinstating the opioid looks like confirmation that it is needed.

Interpreting the result

Meeting the criteria means the opioid must come out, and how that conversation is handled largely determines whether it succeeds. Explain the paradox first and explicitly — the medication is generating the pain it is being given for, so reducing it will help even though that is the opposite of what experience suggests. Patients will not accept a plan to remove their analgesia unless they understand why, and a withdrawal started without that explanation reliably collapses. Withdraw on a planned, time-limited schedule rather than abruptly or open-endedly, and start a central neuromodulator before or during the taper so something is in place as the opioid comes down. Warn explicitly that pain typically worsens transiently during withdrawal before improving; a patient who is not warned will read that as proof the diagnosis was wrong, and that is the commonest point of failure. Treat constipation, nausea and anxiety actively throughout — unmanaged withdrawal symptoms derail more tapers than the pain itself does. Where criteria are not met because the opioid pattern is absent, assess for centrally mediated abdominal pain syndrome instead.

ScoreBandWhat it meansAction
≥ 2 of 3 patterns, on chronic or high-dose opioidsNarcotic bowel syndromeOpioid-induced gastrointestinal hyperalgesia — the analgesia is generating the painPlanned opioid withdrawal with a neuromodulator in place; explain the paradox before starting
Only 1 pattern presentCriteria not metBelow the two-pattern threshold Rome IV requiresReassess over time — the patterns tend to declare themselves as doses escalate further
No opioid exposureCriteria not metChronic abdominal pain without the opioid driverAssess for centrally mediated abdominal pain syndrome

What the Narcotic Bowel Syndrome needs (5 inputs)

Chronic or frequently recurring abdominal pain, occurring most days, treated with acute high-dose or chronic opioids
Rome IV specifies that the pain must occur most days. Intermittent pain with long pain-free intervals does not fit the pattern.
The nature and intensity of the pain is not explained by a current or previous GI diagnosis
A structural diagnosis such as inflammatory bowel disease or chronic pancreatitis may be present — the criterion is that the character or activity of that disease is not sufficient to explain the pain. This is what allows the diagnosis in a patient who already carries a label.
Pain worsens or incompletely resolves with continued or escalating opioid doses
One of three patterns, two of which are required. This is the pattern that most directly contradicts the assumption of under-treatment.
Marked worsening of pain as the dose wanes, improving when opioids are reinstated — 'soar and crash'
Frequently misread as proof that the opioid is essential. The improvement on reinstatement is relief of withdrawal-associated hyperalgesia, not treatment of the underlying pain.
Progression of the frequency, duration and intensity of pain episodes
The trajectory over months. A patient whose episodes are becoming more frequent, longer and more severe on rising doses is describing this pattern.

What it returns

Criteria met or not met
Requires the opioid exposure criterion, the unexplained-pain criterion, and two or more of the three characteristic patterns.
Number of characteristic patterns met
Reported out of three, so it is clear how close a case sits to the threshold.

How it is calculated

Chronic opioid exposure produces hyperalgesia through several convergent mechanisms: upregulation of pronociceptive pathways, glial activation, and impaired descending inhibition — the same descending inhibition that is already compromised in centrally mediated pain. The result is a nervous system that responds to opioid exposure by becoming more, not less, sensitive to visceral input. That accounts for each of the three characteristic patterns directly. Pain worsens on escalation because each dose increase drives further hyperalgesia. The soar-and-crash pattern reflects withdrawal-associated hyperalgesia as levels fall, relieved by reinstating the drug that caused it. And episodes progress because the underlying sensitisation accumulates. Rome IV placing this disorder in the same chapter as centrally mediated abdominal pain syndrome is not incidental: they share a mechanism, and one is frequently the iatrogenic consequence of treating the other badly.

Facts & figures

The three patterns, and how each is usually misread
PatternThe intuitive readingWhat it actually indicates
Pain worsens with escalating dosesThe dose is still too lowEach increase drives further hyperalgesia
Soar and crash around dose timingThe opioid is clearly essential — it worksWithdrawal-associated hyperalgesia relieved by the drug that caused it
Episodes becoming more frequent, longer, more severeThe underlying disease is progressingAccumulating central sensitisation

All three misreadings lead to the same action — increase the opioid — which is why the disorder is self-perpetuating without the diagnosis being made explicitly.

Running the withdrawal
ElementDetail
Explain the paradox firstPatients will not accept removal of analgesia without understanding why it is the cause
Planned, time-limited taperNot abrupt cessation, and not open-ended
Neuromodulator in place before or duringTricyclic or SNRI, so something is working as the opioid comes down
Warn about transient worseningThe commonest point of failure — unwarned patients read it as disconfirmation
Treat withdrawal symptoms activelyConstipation, nausea and anxiety derail more tapers than pain does

The clinical difficulty here is almost entirely in the explanation and the expectation-setting rather than in the pharmacology.

Evidence

Derivation — Rome Foundation, centrally mediated disorders committee

2016

Consensus criteria from the Rome IV committee on centrally mediated disorders of gastrointestinal pain, published in Gastroenterology in 2016 alongside centrally mediated abdominal pain syndrome.

Consensus-derived. The distinctive structural features are the two-of-three pattern requirement, the absence of any duration rule, and the explicit permission for a coexisting structural gastrointestinal diagnosis.

Companion disorder — centrally mediated abdominal pain syndrome

2016

Rome IV defines CAPS in the same chapter, sharing the central sensitisation mechanism.

Placing the two together reflects the clinical sequence: patients with centrally mediated pain are escalated onto opioids and develop narcotic bowel syndrome as an iatrogenic second disorder.

Related opioid complication — AGA 2019

2019

AGA Institute guideline on the medical management of opioid-induced constipation, addressing the other major gastrointestinal consequence of chronic opioid therapy.

Relevant because opioid-induced constipation coexists in most of these patients and must be managed actively during withdrawal, when it is a common reason tapers fail.

How it compares

Narcotic Bowel Syndrome vs Centrally mediated abdominal pain syndrome

Same chapter, same mechanism, opposite treatment — CAPS needs a neuromodulator added, narcotic bowel syndrome needs the opioid removed.

The two share central sensitisation as their mechanism and frequently occur in sequence: a patient with CAPS is escalated onto opioids because the pain is severe and unexplained, and develops narcotic bowel syndrome as a result. Distinguishing them is straightforward once the opioid history is plotted — CAPS pain is continuous and unrelated to dosing, while narcotic bowel syndrome pain tracks the opioid schedule and escalates with it. A patient can have both, and in that case the opioid must come out before the underlying CAPS can be assessed or treated properly.

Open the Centrally mediated abdominal pain syndrome calculator →Keefer L, Drossman DA, Guthrie E, Simrén M, Tillisch K, Olden K, Whorwell PJ. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2016;150(6):1408-1419.

Narcotic Bowel Syndrome vs Opioid-induced constipation

Both are opioid complications and they coexist constantly, but one is a peripheral motility effect and the other a central pain effect — with opposite implications for continuing the drug.

Opioid-induced constipation is managed alongside continued opioid therapy, with laxatives and, where needed, peripherally acting mu-opioid receptor antagonists that preserve analgesia. Narcotic bowel syndrome cannot be managed that way — the opioid itself is the problem and must be withdrawn. Most patients with narcotic bowel syndrome also have opioid-induced constipation, and treating it actively during the taper matters, because withdrawal worsens gastrointestinal symptoms and unmanaged constipation is a common reason patients abandon the plan.

Open the Opioid-induced constipation calculator →

Narcotic Bowel Syndrome vs Under-treated pain from active disease

The differential that matters most, and the reason Rome IV requires two of three patterns rather than one — labelling genuinely under-treated pain as hyperalgesia causes real harm.

A patient with active Crohn's disease, an obstructing stricture or progressing malignancy whose pain worsens on opioids may simply need more analgesia and better disease control. The discriminating features are objective: is the disease actually active on inflammatory markers, imaging or endoscopy, and does the pain track the opioid schedule rather than the disease? The two-of-three threshold, and the requirement that the pain be unexplained by the gastrointestinal diagnosis, exist precisely to prevent this error. Where doubt remains, reassessing disease activity objectively comes before any decision about the opioid.

Pearls & pitfalls

  • Rising doses with rising pain is the signal. It is systematically misread as under-treatment, and that misreading is what perpetuates the disorder.
  • 'Soar and crash' is the most misleading pattern — improvement on reinstating the opioid looks like proof it is needed, but it is relief of withdrawal hyperalgesia.
  • A coexisting structural diagnosis does not exclude this. The test is whether the disease's activity explains the pain, not whether the disease exists.
  • Two of the three patterns are required, not one. The threshold guards against labelling genuinely under-treated pain as hyperalgesia.
  • Explain the paradox before proposing withdrawal. A taper started without that explanation reliably fails.
  • Warn that pain worsens transiently during withdrawal. Unwarned patients interpret it as disconfirmation and resume.
  • Start a neuromodulator before or during the taper, not after — the gap is where tapers collapse.
  • Treat constipation, nausea and anxiety actively throughout; unmanaged withdrawal symptoms derail more tapers than the pain does.
  • There is no duration criterion. The requirement is that pain occurs most days, not that it has lasted three months.
  • Do not frame this as addiction. It is a pharmacological consequence of prescribed treatment, and conflating the two loses the patient.

Critical actions

  • Plot the opioid dose against pain severity over time — the relationship is usually visible once written down and is the most persuasive thing to show the patient.
  • Establish whether any coexisting structural disease is actually active, with objective markers rather than assumption.
  • Explain the mechanism explicitly before proposing any change to the opioid.
  • Agree a planned, time-limited withdrawal schedule rather than abrupt cessation or an open-ended reduction.
  • Start a central neuromodulator before or during the taper.
  • Warn about transient worsening during withdrawal and agree in advance what will happen if it occurs.
  • Manage constipation, nausea and anxiety proactively throughout the taper.
  • Arrange psychological support alongside, since withdrawal in this context is difficult and relapse is common.
  • Do not investigate further for a structural cause once the criteria are met and the work-up is complete.

Why this score exists

Naming this disorder was in part an act of clinical protection. Before it had a name, a patient whose abdominal pain worsened on rising opioid doses had two available explanations — progressive disease or drug-seeking — and both are wrong and both cause harm. The first leads to repeat investigation and sometimes surgery; the second leads to the patient being disbelieved and discharged. The committee's contribution was a third explanation with a mechanism and a treatment. The decision to permit a coexisting structural diagnosis is the criteria's most practically important feature, because the patients in whom this is hardest to see are precisely those who carry an inflammatory bowel disease or chronic pancreatitis label that appears to account for everything. Requiring two of three patterns rather than one was a deliberate guard against over-diagnosis in patients whose pain is genuinely under-treated.

About the creator

  • Laurie Keefer

    First author, Rome IV centrally mediated disorders committee

    Chaired the committee that produced the Rome IV criteria for centrally mediated gastrointestinal pain disorders.

  • Douglas A. Drossman

    Co-author; much of the original description of narcotic bowel syndrome

    Contributed the foundational descriptions of narcotic bowel syndrome and the withdrawal approach used to treat it.

Limitations

  • No opioid dose threshold is specified — 'acute high-dose or chronic' is qualitative, and practice varies widely on what counts.
  • No duration criterion, which is pragmatic but leaves the boundary with acute opioid use undefined.
  • Distinguishing hyperalgesia from genuinely under-treated pain rests on clinical judgement, and getting it wrong in either direction causes harm.
  • The requirement that pain be unexplained by a coexisting GI diagnosis depends on how thoroughly disease activity has been assessed.
  • Consensus criteria with no validation study, which matters more here than usual because the diagnosis commits a patient to opioid withdrawal.
  • Says nothing about how the withdrawal should be conducted, despite that being where the clinical difficulty lies.
  • Does not address opioid dependence or withdrawal management, which frequently need specialist input.
  • The evidence base for treatment rests largely on case series and expert consensus rather than randomised data.

If you are the patient

Narcotic bowel syndrome is a situation where strong painkillers — morphine, oxycodone, codeine and similar — have started to cause the abdominal pain they were given to treat. It sounds strange, and most people find it hard to believe at first, which is completely understandable. What happens is that long-term use of these medicines makes the nervous system more sensitive to pain rather than less, so each increase in dose gives short-term relief followed by worse pain than before. Two patterns are typical: the pain gets worse as the dose goes up, and the pain flares badly as each dose wears off then settles when the next one is taken — which naturally makes it feel as though the medicine is essential. The only treatment that works is coming off the opioid, with proper support and on a planned schedule rather than suddenly. Your doctor will usually start a different type of medicine first — one that calms nerve signalling rather than blocking pain — so there is something in place as the opioid reduces. One thing to expect and prepare for: the pain often gets worse for a while during the reduction before it gets better. That is part of the process, not a sign the plan is wrong, and knowing it in advance makes a real difference to getting through it. This is not addiction and it is not your fault — it is a known effect of a medicine that was prescribed in good faith.

Frequently asked questions

What are the Rome IV criteria for narcotic bowel syndrome?#

Chronic or frequently recurring abdominal pain, occurring most days, treated with acute high-dose or chronic opioids; pain whose nature and intensity is not explained by a current or previous gastrointestinal diagnosis; and two or more of: pain worsening or incompletely resolving with continued or escalating doses, marked worsening as the dose wanes with improvement on reinstatement, or progression in the frequency, duration and intensity of episodes.

What is 'soar and crash'?#

The pattern where pain flares markedly as the opioid dose wanes and improves when the next dose is taken. It is one of the three characteristic patterns and the most frequently misinterpreted, because the improvement on reinstatement looks like proof the opioid is working. What it actually reflects is relief of withdrawal-associated hyperalgesia — the drug relieving a problem it created.

Can you diagnose this in a patient with Crohn's disease or chronic pancreatitis?#

Yes, and Rome IV says so explicitly. A patient may carry a structural diagnosis provided its character or activity does not sufficiently explain the pain. The test is objective — are inflammatory markers, imaging or endoscopy consistent with active disease? A patient with quiescent Crohn's on escalating opioids with worsening pain can have narcotic bowel syndrome, and this is the group in whom it is hardest to see.

Is narcotic bowel syndrome the same as opioid addiction?#

No. It is a pharmacological consequence of prescribed opioid therapy — hyperalgesia driven by changes in pain signalling — not a disorder of craving or compulsive use. Conflating the two is both inaccurate and clinically counterproductive, because patients who feel accused of addiction disengage. Dependence may coexist and may need managing, but it is a separate issue from the hyperalgesia.

How is narcotic bowel syndrome treated?#

By withdrawing the opioid on a planned, time-limited schedule, with a central neuromodulator started before or during the taper. Explaining the paradox to the patient first is essential — a withdrawal started without that understanding reliably fails. Constipation, nausea and anxiety need treating actively throughout, since unmanaged withdrawal symptoms derail more tapers than the pain does.

Does the pain get worse during withdrawal?#

Typically yes, transiently, before it improves. This is the single most important thing to warn a patient about in advance, because an unwarned patient interprets the worsening as evidence the diagnosis was wrong and resumes the opioid. Agreeing beforehand what will happen if pain flares, and having a plan for it, is what gets people through the taper.

Why does Rome IV require two of the three patterns?#

To guard against over-diagnosis. A single pattern — pain not fully resolving on opioids, for instance — is common in genuinely under-treated pain from active disease. Requiring two, alongside the criterion that the pain is unexplained by a gastrointestinal diagnosis, makes it much less likely that a patient who simply needs better disease control is labelled as having hyperalgesia and has their analgesia withdrawn.

Is there a duration requirement?#

No. Unlike almost every other Rome IV disorder there is no three-month or six-month rule. The requirement is that the pain occurs most days and that the opioid exposure is acute high-dose or chronic. That structure means the diagnosis can be made as soon as the pattern is recognisable rather than after a fixed waiting period.

Related calculators

  • Centrally Mediated Abdominal Pain (CAPS) — Rome IV — continuous pain unrelated to gut events
  • Opioid-Induced Constipation — Rome IV — constipation tied to opioid therapy
  • Rome IV Criteria for IBS — Irritable bowel syndrome diagnosis and subtype
  • Functional Dyspepsia — Rome IV — with PDS and EPS subtyping
  • CAGE — Alcohol use disorder screening (4 questions)

References

Original / primary reference

  1. Keefer L, Drossman DA, Guthrie E, Simrén M, Tillisch K, Olden K, Whorwell PJ. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2016;150(6):1408-1419 (Rome IV).

Related opioid complications

  1. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156(1):218-226.
  2. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6):1393-1407.

Last updated August 1, 2026. Clinical knowledge base written and curated by GastroAGI Team from primary medical literature.

Written from primary literature and not yet independently clinically reviewed.

For use by qualified healthcare professionals. This calculator supports clinical judgement and does not replace it.